1. In Vivo
  2. >>Innovation

Intuitive Surgical and Computer Motion Merge to Create Concentrated Robotics Play

Tired of fighting each other in court, the two leading robotics companies have decided to render their IP differences moot through a merger.

For many companies trying to get innovative technology accepted in the marketplace, intellectual property becomes a critical battleground. But when it becomes the primary battleground, IP litigation can divert and distort the companies from their main goal: gaining adoption for their technology. That, at least, is what happened in surgical robotics, a highly promising, but to date poorly penetrated innovation. And now, tired of fighting each other in court, the two leading robotics companies, Sunnyvale, CA-based Intuitive Surgical Inc. and Santa Barbara, CA-based Computer Motion Inc. , have decided to render their IP differences moot through a merger of the two companies [See Deal].

Discussing the deal, Lonnie Smith, Intuitive's CEO who will run the combined company, noted that "Clearly, we were both pouring...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on In Vivo for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Innovation

Enabling Precision Medicine At Scale Through Digital Innovation And AI

 
• By Cristal Thompson and Justyna Anna Lisowska

AI is reshaping clinical trials by enabling precision medicine, accelerating patient stratification, optimizing trial design, and transforming complex data into actionable insights for faster, more effective drug development.

How Rapport Transferred A Decade Of Big Pharma Neuroscience Expertise To Biotech

 
• By David Wild

Rapport Therapeutics CEO discusses the company's novel approach to AMPA modulation and why strategic externalization from J&J is accelerating neuroscience innovation.

Podcast: Merck’s Vision For Making Digital Health Redundant

 
• By Jo Shorthouse

Merck KGaA's Emre Ozcan outlines the company's systematic approach to integrating digital solutions across the care continuum in specialty pharmaceuticals, moving from technology-first to patient-need-first strategies.

Does ReproNovo’s $65m Raise Signal An Oasis In The Fertility Investment Desert?

 
• By Jo Shorthouse

ReproNovo's $65m Series A targets the $1.5bn male infertility market with the first potential oral therapy. Its first-in-class approach to underserved conditions like adenomyosis positions it as an attractive acquisition target in fertility's concentrated market.

More from In Vivo

Does ReproNovo’s $65m Raise Signal An Oasis In The Fertility Investment Desert?

 
• By Jo Shorthouse

ReproNovo's $65m Series A targets the $1.5bn male infertility market with the first potential oral therapy. Its first-in-class approach to underserved conditions like adenomyosis positions it as an attractive acquisition target in fertility's concentrated market.

Moderna Veteran Launches Icelandic mRNA Firm Despite US Retreat

 
• By David Wild

Axelyf raises $2.6m seed round for lipid nanoparticle delivery platform on heels of end to US federal support for mRNA vaccines.

Podcast: Tevard CEO Sees Hope For His Daughter In Company’s tRNA Platform

 
• By David Wild

Tevard Biosciences CEO Daniel Fischer discusses how engineered suppressor tRNAs overcome nonsense mutations, restoring full-length protein production to treat rare genetic diseases like Dravet syndrome.